Elevated Release of Presynaptic Glutamate: The Potential Pathogenesis of Anti‐ NMDAR Encephalitis‐Associated Seizures
CNS Neuroscience & Therapeutics · 2025
DOI: 10.1111/cns.70585 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Hongmi Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, China. Hauptthemen laut MEDLINE: Seizures, Anti-N-Methyl-D-Aspartate Receptor Encephalitis, Glutamic Acid, Presynaptic Terminals. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
The pathogenesis of anti‐N‐methyl‐D‐aspartate receptor encephalitis (anti‐NMDAR encephalitis)‐associated seizures remains elusive.
Methods
Mice were injected with GluN1 359–378 peptide to construct a model of anti‐NMDAR encephalitis. Next, the expression of NMDAR antibodies (NMDAR‐Ab) was detected in serum samples. The electroencephalograms (EEGs) of mice were recorded. Afterward, neuronal action potentials (APs) and miniature excitatory postsynaptic currents (mEPSCs) were examined following exposure to serum derived from model mice. The expression levels of subunits of the NMDA receptor (GluN1, GluN2B) and glutamate vesicular transporter 1 (Vglut1) were quantified via Western blot analysis. Additionally, mice were injected with pentylenetetrazol (PTZ) to construct an in vivo model of status epilepticus (SE). Lastly, neurons exposed to mouse serum were incubated in a magnesium‐free solution (Mg 2+ ‐free) for 1, 2, and 3 h, and APs were assessed.
Results
Following the administration of immunogenic peptide GluN1 359–378 , serum NMDAR‐Ab was detected. EEG recording revealed that 68.75% (11/16) of mice receiving GluN1 359–378 exhibited epileptiform discharges. Moreover, the frequency of neuronal APs and mEPSCs following exposure to serum derived from mice receiving GluN1 359–378 was increased. The surface expression level of the GluN1 protein was significantly decreased, whereas that of the total Vglut1 protein was increased. Moreover, the seizure latency of mice receiving GluN1 359–378 was significantly shortened. Finally, after 1 to 2 h of incubation with Mg 2+ ‐free solution, the frequency of neuronal APs following exposure to serum derived from mice receiving GluN1 359–378 was increased.
Conclusion
To the best of our knowledge, this is the first study to demonstrate that increased glutamate release may increase seizure susceptibility in patients with anti‐NMDAR encephalitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, China.
ORCID-Profile: Sijun Li
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Huang, H., Huang, Y., Li, S., Wu, Y., Yang, S., & Wu, Y. (2025). Elevated Release of Presynaptic Glutamate: The Potential Pathogenesis of Anti‐ NMDAR Encephalitis‐Associated Seizures. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70585
Vancouver
Huang H, Huang Y, Li S, Wu Y, Yang S, Wu Y. Elevated Release of Presynaptic Glutamate: The Potential Pathogenesis of Anti‐ NMDAR Encephalitis‐Associated Seizures. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70585
BibTeX
@article{Huang2025,
author = {Huang, Hongmi and Huang, Yifei and Li, Sijun and Wu, Ying and Yang, Shengyu and Wu, Yuan},
title = {Elevated Release of Presynaptic Glutamate: The Potential Pathogenesis of Anti‐ NMDAR Encephalitis‐Associated Seizures},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
doi = {10.1111/cns.70585}
}
EUVIMED